We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) came under pressure in the premarket on Tuesday after the company’s Q1 2025 ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know. Regeneron ...

Regeneron Pharmaceuticals (NASDAQ:REGN) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD (aflibercept) Injection 8 mg in wet age ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion ...

Regeneron holds exclusive U.S. rights ... gaining an additional 0.51% on the Nasdaq Global Select Market. The views and opinions expressed herein are the views and opinions of the author and ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...